Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Evoke Pharma (EVOK) FCF Margin (2020 - 2025)

Historic FCF Margin for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to 12.18%.

  • Evoke Pharma's FCF Margin rose 186600.0% to 12.18% in Q3 2025 from the same period last year, while for Sep 2025 it was 23.05%, marking a year-over-year increase of 387500.0%. This contributed to the annual value of 53.26% for FY2024, which is 429600.0% up from last year.
  • Latest data reveals that Evoke Pharma reported FCF Margin of 12.18% as of Q3 2025, which was up 186600.0% from 15.06% recorded in Q2 2025.
  • In the past 5 years, Evoke Pharma's FCF Margin ranged from a high of 12.18% in Q3 2025 and a low of 3265.97% during Q1 2021
  • Over the past 5 years, Evoke Pharma's median FCF Margin value was 132.31% (recorded in 2022), while the average stood at 366.91%.
  • As far as peak fluctuations go, Evoke Pharma's FCF Margin plummeted by -540384600bps in 2021, and later surged by 28799500bps in 2022.
  • Quarter analysis of 5 years shows Evoke Pharma's FCF Margin stood at 553.9% in 2021, then surged by 43bps to 314.72% in 2022, then surged by 79bps to 66.0% in 2023, then soared by 43bps to 37.48% in 2024, then soared by 67bps to 12.18% in 2025.
  • Its last three reported values are 12.18% in Q3 2025, 15.06% for Q2 2025, and 32.38% during Q1 2025.